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Protocol
AbstrACt
background In 2013, the stillbirth rate in the UK was 4.2 
per 1000 live births, ranking 24th out of 49 high-income 
countries, with an annual rate of reduction of only 1.4% 
per year. The majority of stillbirths occur in normally 
formed infants, with (retrospective) evidence of placental 
insufficiency the most common clinical finding. Maternal 
perception of reduced fetal movements (RFM) is associated 
with placental insufficiency and increased risk of subsequent 
stillbirth. This study will test the hypothesis that the 
introduction of a package of care to increase women’s 
awareness of the need for prompt reporting of RFM and 
standardised management to identify fetal compromise with 
timely delivery in confirmed cases, will reduce the rate of 
stillbirth. Following the introduction of a similar intervention 
in Norway the odds of stillbirth fell by 30%, but the efficacy 
of this intervention (and possible adverse effects and 
implications for service delivery) has not been tested in a 
randomised trial.
Methods We describe a stepped-wedge cluster trial design, 
in which participating hospitals in the UK and Ireland will 
be randomised to the timing of introduction of the care 
package. Outcomes (including the primary outcome of 
stillbirth) will be derived from detailed routinely collected 
maternity data, allowing us to robustly test our hypothesis. 
The degree of implementation of the intervention will 
be assessed in each site. A nested qualitative study will 
examine the acceptability of the intervention to women and 
healthcare providers and identify process issues including 
barriers to implementation.
Ethics and dissemination Ethical approval was obtained 
from the Scotland A Research Ethics Committee (Ref 13/
SS/0001) and from Research and Development offices in 
participating maternity units. The study started in February 
2014 and delivery of the intervention completed in December 
2016. Results of the study will be submitted for publication 
in peer-reviewed journals and disseminated to local 
investigating sites to inform education and care of women 
presenting with RFM.
trial registration number www. clinicaltrials. gov 
NCT01777022.
Version Protocol Version 4.2, 3 February 2017.
IntroduCtIon
Stillbirth
Stillbirth, defined in the UK as a baby with no 
signs of life after 24 weeks of completed preg-
nancy,1 remains the major cause of perinatal 
mortality in high-income environments, with 
a recent series of papers in the Lancet on still-
birth issue calling for renewed action in this 
area.2 There is no single ‘cause’ of stillbirth, 
and a significant proportion of stillbirths 
remain unexplained, but fetal growth restric-
tion (FGR), maternal hypertension and low 
socioeconomic status are among the identifi-
able risk factors.3
The concept that more can be done to 
reduce stillbirth in the UK and Ireland is 
supported by data showing a marked variation 
strengths and limitations of this study
 ► This trial directly addresses the need for studies 
of the information given to women regarding fetal 
movements and the subsequent management of 
reduced fetal movements identified by Confidential 
Enquiries into Antepartum Stillbirths, Systematic 
Reviews and the Stillbirth Priority Setting Partnership.
 ► A stepped-wedge cluster trial design in combination 
with routinely collected maternity data allows the 
trial to be adequately powered to detect a difference 
in stillbirth as a primary outcome.
 ► The pragmatic nature of the study represents 
the potential impact of the introduction of such 
standardised care into clinical practice.
 ► The nested qualitative study will provide information 
regarding the acceptability of the intervention and 
identify barriers and facilitators to its adoption.
 ► The lack of information on resource use before 
and throughout the study period limits the ability to 
understand the consequences of the intervention on 
maternity unit workload.
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in rates between resource rich countries, when similar 
definitions of stillbirth are used.2 Notably, the UK has a 
higher rate than comparable resource rich countries such 
as Germany, Netherlands, New Zealand and Norway with 
rates in the UK some 50% greater than those of the Neth-
erlands. Disappointingly, the annual rate of reduction 
in stillbirth from 2000 to 2014 in the UK was only 1.4% 
compared with 6.8% in the Netherlands and 2.8% in New 
Zealand.2 Rates of stillbirth in Scotland (3.7 per 1000 
births in 2014) and Ireland (4.4 per 1000 live births in 
2013) are similar to rates in England and Wales at 4.2 per 
1000 live births (England and Wales, 2014).4 The reduc-
tion of avoidable harm for women and babies is viewed 
as a major priority for Government and its agencies 
throughout the UK and Ireland. Consequently, several 
initiatives have been developed by national governments 
in the UK and Ireland including the Scottish Government 
Stillbirth Working Group, NHS England Saving Babies’ 
Lives Care Bundle and the Welsh Assembly 1000 Lives 
Plus strategy. These strategies have identified the need 
for better evidence to guide efforts to prevent stillbirths.
Using a robust priority setting strategy5 the Lancet 
Stillbirth’s series steering committee identified issues 
around detection and management of reduced fetal 
movements (RFM) among the top 10 key research ques-
tions on prevention and management of stillbirth.6 This 
was confirmed in the UK-based Stillbirth Priority Setting 
partnership involving over 1700 parents and profes-
sionals which identified two relevant issues among the 
highest ranked research questions regarding stillbirth: 
(1) which investigations identify a fetus at risk of stillbirth 
after a mother believes she has experienced reduced fetal 
movements? and (2) would more accessible evidence-
based information on signs and symptoms of stillbirth 
risk, designed to empower women to raise concerns with 
healthcare professionals, reduce the incidence of still-
birth?7 Thus, RFM has been identified as a highly relevant 
area of study by parents, professionals and researchers.
rFMs, stillbirth and placental insufficiency
There is a clear association between maternal perception 
of RFM and late stillbirth dating back over four decades.8 
In a recent series of 2000 women, the adjusted OR 
(95% CI) of late stillbirth in women with RFM (compared 
with controls) was 2.37 (1.29 to 4.35).9 One international 
study of 1714 women who experienced a stillbirth found 
that 30% had noted significant RFM prior to the diag-
nosis of stillbirth.10 Although the mechanisms have not 
been fully delineated, it is likely that RFM and stillbirth 
are linked by a common pathology, that of placental 
dysfunction.11 There is good evidence linking placental 
dysfunction and RFM. Compared with controls with an 
active fetus women who have fewer fetal movements on 
ultrasound scan immediately prior to caesarean section 
are more likely to have umbilical cord gas measurements 
indicative of acidaemia, hypoxaemia and hypercapnia.12 
Women delivering within 1 week of an episode of RFM 
show differences in placental structure and function 
which are reminiscent of those seen in FGR and still-
birth.13 14 Additionally, the odds of FGR (defined as being 
at less than the 10th centile for gestation adjusted birth 
weight) were greater in women with RFM compared with 
controls (adjusted OR 1.6, 95% CI 1.1 to 2.2).15 Taken 
together these data are strong evidence that placental 
dysfunction is associated with RFM, and a causative 
pathway seems likely.
The evidence linking placental dysfunction and still-
birth is even stronger; a systematic review of placental 
pathology in stillbirths described abnormalities in up to 
65% of cases.16 Among the 291 stillbirths in Scotland in 
2010, 137 (47%) had evidence of placental dysfunction.17 
Given that the placenta was examined in only 80% of 
stillbirths, the true prevalence of placental dysfunction is 
likely to be higher. In addition, between 20% and 40% of 
stillborn babies are reported to have FGR, as defined by a 
birth weight less than the 10th centile.18 Additionally, the 
Lancet report notes that ‘placental pathologies accounted 
for one in four deaths across all gestational ages, and were 
contributory or causal in more than half of cases.’6 Given 
that stillbirth is strongly related to placental dysfunction, 
and RFM is a ‘biomarker’ of placental dysfunction then 
better management of women presenting with RFM 
focusing on the detection of placental dysfunction might 
reduce the risk of stillbirth.
Formal fetal movement counting
Although prenatal detection of FGR is improved by fetal 
movement counting,19 a systematic review,20 and a large 
and influential cluster randomised trial (which dominates 
the systematic review) showed that routine fetal move-
ment counting using the count to 10 charts had no effect 
on perinatal mortality.21 Thus, the National Institute for 
Health and Social Care Excellence recommended that 
‘Routine formal fetal movement counting should not 
be offered.’22 Importantly, the large cluster randomised 
trial tested a specific alarm limit for RFM, but did not 
recommend a specific management strategy for women 
who did present with RFM. There were two important 
observations from this study, first that in both groups 
the perinatal mortality rate was lower than contempo-
rary or subsequent periods in the UK, and second that 
more women in the fetal movement counting arm came 
in with a live baby who subsequently died compared with 
the control arm (19 vs 11), suggesting that one reason 
the strategy failed to reduce perinatal mortality was inade-
quate investigation and management of those presenting 
with RFM.21
optimal strategy for determining rFM to prompt maternal 
presentation to the maternity service
Maternal concern about RFM is a common reason to 
contact maternity services with between 6% and 15% 
of women presenting during the third trimester.23 24 
Nevertheless, delays in reporting RFM to maternity care 
providers may increase the risk of adverse outcome.25 26 
The lack of good-quality information given to women 
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about fetal movements has been highlighted as an 
example of suboptimal care in Confidential Enquiries 
into Antepartum Stillbirth.27 28 Qualitative studies suggest 
that women frequently perceive RFM 2 days prior to the 
diagnosis of fetal death, and in some cases contractions 
were misinterpreted as fetal movements.29 Therefore, 
giving information to women regarding fetal movements 
and when they should be concerned about RFM is a key 
component of an intervention to reduce stillbirth.
However, giving clear information about RFM can be 
challenging as there is no uniform threshold of fetal 
movements below which perinatal morbidity increases,24 
and no evidence that a specific threshold performs 
better than maternal perception of RFMs alone.8 Current 
guidelines from the Royal College of Obstetricians and 
Gynaecologists (RCOG) and Perinatal Society of Australia 
and New Zealand (PSANZ),30 31 informed by a large 
Norwegian study,32 suggest that it is maternal perception of 
decreased fetal movement which is important. Therefore, 
information for pregnant women in this study (shown in 
online supplementary file 1) described the importance 
of fetal movements, the need to get to know normal fetal 
activity, how fetal movements change in late pregnancy 
and who to contact if the mother perceives RFM. The 
educational package aimed to ensure that these messages 
were reinforced by staff behaviour at antenatal contacts.
optimal strategy for investigation and management of women 
presenting with rFM
A recent systematic review found there are no proven 
strategies for the investigation and management of 
women presenting with RFM.33 Cardiotocography (CTG) 
is routinely used to ascertain fetal well-being, and it is 
the cornerstone of the RCOG guideline.31 However, data 
from Norway suggest that ultrasound assessment of fetal 
size is often the most helpful investigation, performing 
well on both an absolute basis, and compared with other 
interventions.34 In a series of over 3000 women with RFM, 
ultrasound (including measurement of fetal biometry and 
liquor volume) was found to be useful in detecting abnor-
malities in 11.6% of scans. In 71% of women in whom 
an abnormality was found, ultrasound was the only tech-
nique that detected an abnormality. Additionally, 85% 
of abnormalities detected by ultrasound were important 
in informing the clinical management of the woman.34 
These data are supported by a smaller UK study which 
found that abnormalities detected on CTG or ultrasound 
scan were most strongly associated with adverse outcome 
in women with RFM, with identification of abnormal esti-
mated fetal growth centile on scan being the test most 
highly predictive of poor outcome.35 Perhaps this is not 
surprising, given the strong association between RFM 
and placental dysfunction and the central importance 
of ultrasound in the identification and management of 
small for gestational age babies.36 Given these data, it is 
concerning that a survey of clinicians in Scotland showed 
that fewer than 5% would routinely refer women with 
RFM for ultrasound examination (unpublished data 
from June 2012), and a survey of 223 UK midwives and 
obstetricians described that 17.9% of respondents would 
perform an ultrasound scan.37 These views of clinicians 
may reflect the variable quality of local guidelines, which 
are frequently not based on national recommendations, 
even those for which there is strong evidence.38 The vari-
ation in information given to women and subsequent 
management of RFM has been highlighted as sources 
of suboptimal care in two confidential enquiries into 
antepartum stillbirth.27 28 Therefore, we believe that 
current investigation of women presenting with RFM is 
inadequate, hence using the best available evidence, we 
have drafted what we consider to be a robust evaluation 
protocol for investigation of women with RFM.
Potential efficacy of a package of intervention for rFM
Supportive data for the package of interventions used 
in this study (information for women and standardised 
management protocol) come from a large observational 
‘clinical quality improvement study’ in Norway which 
found a significant fall in rates of stillbirth (from 3.0/1000 
to 2.0/1000 (OR 0.67, 95% CI 0.48 to 0.93)) after the 
introduction of an intervention package consisting of 
written information for women about awareness of RFM 
combined with consensus guidelines for health profes-
sionals about their management.32 Although this study 
was not randomised, and therefore constitutes only level 
II-3 evidence, it has informed recommendations from the 
RCOG and PSANZ that ‘women should be advised to be 
aware of their baby’s individual pattern of movements 
and that if they are concerned about a reduction in or 
cessation of fetal movements… they should contact their 
maternity unit.’30 31 Following initial publication of the 
Norwegian study, a reanalysis was required as discrepan-
cies between stillbirth rates in the study and the Medical 
Birth Registry of Norway were identified. This reanalysis 
found the reduction in stillbirth rates was of borderline 
statistical significance (OR 0.72, 95% CI 0.50 to 1.03). 
The authors concluded that further studies were needed 
to determine whether this approach was associated with a 
reduction in stillbirth.39
Importantly, in the Norwegian study, there was no 
increase in the proportion of women who presented 
with RFM when rates were compared before and after 
the intervention.32 However, women with RFM presented 
significantly earlier to hospital than they had hitherto, 
potentially allowing time for intervention to reduce 
perinatal mortality. These data suggest that a package of 
interventions encouraging women with RFM to present 
early to hospital, combined with a structured approach to 
their management might reduce rates of stillbirth without 
contributing to a large increase in admissions antenatally.
Potential harms of a package of care around increased 
awareness and optimised management of rFM
Any clinical intervention which aims to improve outcomes 
also has the ability to do harm. Thus, it is essential that 
the intervention proposed is rigorously evaluated using 
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the gold standard technique of a randomised trial, 
rather than being introduced as a service development. 
When the study began, there was a small window of 
opportunity to do this, as the enthusiasm to improve 
current management of RFM is such that routine intro-
duction of the package of care is unlikely to be delayed 
much further than the current scheduled end date of 
this study. Possible harms of a package of care consisting 
of a management plan for identification and delivery of 
the ‘at risk’ fetus, together with strategies for increasing 
pregnant women’s awareness of the need to report early 
include increased maternal anxiety and increased inter-
vention (including hospital admission, induction of 
labour and caesarean section) which itself is associated 
with pregnancy-related complications. The available 
evidence is reassuring on some of these issues. A system-
atic review of 23 publications from 16 studies found 
three studies involving 2030 women addressing maternal 
concern and an additional three studies involving 1468 
women investigating maternal–fetal attachment. These 
demonstrated no evidence of increased maternal anxiety 
and results regarding maternal–fetal attachment were 
discordant.40 In the Norwegian service development 
study, the package of care increased rates of follow-up of 
women, but there was no increase in admissions overall, 
admissions for induction or admissions for emergency 
caesarean section32—again, while reassuring these 
outcomes require formal evaluation in a randomised 
and relevant setting to the UK and Ireland. The final 
possible harm of the package is around increased 
resource use, and the opportunity cost of focusing on 
RFM rather than other potential methods to prevent 
stillbirth.
rAtIonAlE
The aim of this study is to test the hypothesis that a 
package of interventions consisting of strategies for 
increasing pregnant women’s awareness of the need 
to report early when they perceive a reduction in fetal 
movements, followed with a management plan for identi-
fication and delivery of the ‘at risk’ fetus in such women, 
will reduce rates of stillbirth.
study objECtIVEs
Primary objective
The primary objective is to answer the research question 
‘Does the introduction of a protocol for detection and 
management of decreased fetal movements reduce rates 
of stillbirth?’
The secondary objectives are to answer the following 
research questions:
 ► What is the effect of the intervention on rates of cae-
sarean section and induction of labour?
 ► What is the effect of the intervention on rates of ad-
mission to the neonatal intensive care unit?
 ► What is the effect of the intervention on the propor-
tion of women with FGR remaining undelivered by 40 
weeks’ gestation?
 ► What is the acceptability of such a package of care to 
pregnant women and their healthcare providers?
 ► What other process outcomes are influenced by the 
intervention, such as healthcare provider/patient in-
teractions?
EndPoinTS
Primary outcome
The primary endpoint is stillbirth (antepartum and intra-
partum). We will use the UK definition of stillbirth which 
is ‘a baby delivered without signs of life after 23+6 weeks.’4 
Where gestation is uncertain we will include all babies 
with a birth weight of 500 g or more.
secondary endpoints
Other measures of perinatal mortality including:
 ► stillbirth at 37 weeks’ gestation and above;
 ► stillbirth at 28 weeks’ gestation and above (WHO defi-
nition of stillbirth);
 ► stillbirth at 22 weeks’ gestation and above (interna-
tional stillbirth alliance definition);
 ► stillbirths among normally formed infants of 22 weeks’ 
gestation and above, 24 weeks’ gestation and above, 
28 weeks’ gestation and above and 37 weeks’ gestation 
and above;
 ► perinatal mortality (defined as stillbirth at 24 weeks’ 
gestation and above and deaths in the first 7 days of 
life);
 ► rates of caesarean section;
 ► rates of induction of labour (for any indication);
 ► rates of elective delivery (induction of labour and cae-
sarean section prior to the onset of labour) overall;
 ► rates of induction of labour at 39 weeks’ gestation or 
later;
 ► mean gestation at induction of labour;
 ► rates of admission to the neonatal unit (and their rea-
sons);
 ► rates of admission to the neonatal unit for more than 
48 hours;
 ► rates of admission to the neonatal unit for term babies 
(those born at 37 weeks 0 days or greater);
 ► proportion of infants with FGR (less than the fifth 
centile, customised for gender) remaining undeliv-
ered at or after 40 weeks’ gestation;
 ► birth weight centile (according to the Intergrowth 
birth weight centile calculator at https:// inter-
growth21. tghn. org);
 ► rates of spontaneous vaginal delivery.
Other secondary outcomes are the baby parameters:
 ► gestation at birth
 ► proportion of babies born preterm (<37 weeks’ ges-
tation)
 ► gender of the baby
 ► birth weight of the baby
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 ► Apgar score at 5 min
 ► proportion of babies with 5 min Apgar score <7
 ► proportion of babies with 5 min Apgar score <4
 ► resuscitation required at birth.
We will also collect the following data: maternal age, 
maternity unit of delivery, birth weight, gestation of 
delivery, parity, gestation, sex, smoking (current and ever), 
maternal body mass index (BMI), number of babies (one 
or more), ethnicity (to allow a customised birth weight 
centile to be generated), method of delivery, deprivation 
category (where available) and other neonatal variables 
including Apgar score and encephalopathy. Adjustment 
will be made for the following variables: maternal age, 
maternity unit of delivery, parity, smoking status, maternal 
BMI, number of babies (one or more) and ethnicity.
study dEsIgn
This is a multicentre, stepped-wedge cluster randomised 
trial of a package of care consisting of a management 
plan for identification and delivery of the ‘at risk’ fetus, 
together with strategies for increasing pregnant women’s 
awareness of the need to report RFM early. The trial 
developed from a planned quality improvement project 
proposed by the Scottish Government to reduce still-
births. This was planned to emphasise the importance of 
fetal movement monitoring and was to be rolled out to all 
NHS maternity units in Scotland. However, prior to this 
change it was agreed that the roll-out could be performed 
in such a way as to allow the assessment of the effect of 
the intervention, the stepped-wedge design would be the 
natural choice in this circumstance.
The study will take place in participating hospitals 
in the UK and Ireland (a complete list is available at 
http://www. crh. ed. ac. uk/ affirm/ randomised- hospi-
tals/). A nested qualitative study will examine the 
acceptability of the intervention to patients and health-
care providers and identify process issues (barriers to 
implementation). Clinical audit (detailed in online 
supplementary file 2) conducted after the change in 
practice will be used to determine the effect of inter-
ventions on process outcomes (eg, number of women 
presenting with RFMs, interval between perceiving RFMs 
and presentation to hospital, number of ultrasound 
scans, number of admissions for induction of labour). A 
diagram indicating randomisation of hospital groupings 
in the stepped-wedge design is shown in figure 1.
The interventions will be introduced over a 32-month 
period. Data will be collected over a 36-month period. 
Data in the ‘active phase’ after introduction of the 
intervention will be compared with data in the ‘control 
phase’—the period during which usual care processes 
in study sites are followed from study start to the time 
of introduction of the intervention. Given that it will 
take individual units some time (A) to effect change in 
management in their unit from time of introduction of 
the intervention and (B) that it will take some time for 
this change in practice to impact on clinical outcomes, 
we plan a ‘washout’ period of 2 months after the intro-
duction of the intervention during which data will not 
be included in either group for analysis (figure 1). Data 
will be collected 4 months after the last birth, a further 
2 months has been included for data analysis, giving a 
total study duration of 42 months.
study PoPulAtIon
number of participants
Participants will be those delivering at all the sites over 
the study period (36 months). All eligible women will 
be recruited to the cluster randomised controlled trial. 
Based on previous delivery numbers, after accounting 
for a washout period of 2 months (and assuming no with-
drawals or losses to follow-up) this is estimated to be a 
total of around 143 140 women per annum. A subset of 
around 30 participating women and 30 midwives, sonog-
raphers and obstetricians will be recruited to the nested 
qualitative study, which is based in the Scottish sites.
Inclusion criteria
We will include all women delivering at one of the partic-
ipating maternity units for the duration of the study. 
Women who have been seen at any of the maternity units 
but who deliver at home will not be included. The dura-
tion of the study will be 42 months from the start of the 
trial (1 February 2014). For practical reasons, participants 
Figure 1 Stepped-wedge design. The shaded areas (both light and dark) indicate periods in which the interventions are 
being implemented. The lighter areas indicate the ‘transition’ period during which data will not be collected for the control or 
intervention group. The order in which hospital groupings implement the interventions will be determined via randomisation.
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for the nested qualitative study will be recruited from the 
participating units in Scotland.
Exclusion criteria
We will exclude women as follows:
 ► women for whom data on delivery outcomes are still 
unavailable 4 months after the date of delivery;
 ► women delivering in the ‘washout’ period in each 
unit.
Members of the trial management group and partic-
ipants who do not speak/understand English will be 
excluded from participating in the nested qualitative 
study.
Identifying participants
Women will be identified from those whose data are 
included in routine data returns from each unit. Poten-
tial participants for the nested qualitative study will be 
identified from those attending antenatal clinics in partic-
ipating hospitals, and/or local staff.
Consenting participants
The main study is a stepped-wedge cluster randomised 
trial of a package of care which would be introduced in 
many of the participating units regardless of whether the 
trial was ongoing or not and the trial uses only routinely 
collected data on participants. The ethics committee 
indicated that formal individual patient consent is not 
necessary for the main trial. Participants in the nested 
qualitative study will be asked for individual consent.
screening for eligibility
As participants are not directly recruited we will not 
perform any specific screening tests for this aspect of 
this project. Participants for the nested qualitative study 
will be: (1) Pregnant women attending hospitals who 
are participating in the main trial in Scotland. Purposive 
sampling will ensure that the final sample set includes 
women who have and who have not experienced RFM, 
both before and after the introduction of the intervention; 
(2) Hospital staff (including midwives, ultrasonographers 
and obstetricians/radiologists) working in participating 
hospitals in Scotland. There will be no specific screening 
tests for eligibility for the nested qualitative study, except 
that women who have experienced a stillbirth in the 
index pregnancy will not be approached.
Ineligible and non-recruited participants
Potential participants for the nested qualitative study who 
are not approached or who decline will have no specific 
interventions/procedures.
Withdrawal of study participants
The nature of a cluster randomised study is such that 
it is not possible for the participant to withdraw from 
the ‘cluster’ unless she changes maternity unit part way 
through her pregnancy. We plan to collect routinely 
recorded anonymised data; patients have the right to opt 
out of having their data used—if this happens their data 
would be excluded from the study database (eg, under 
the Confidentiality and Security advisory Group Report 
2002 and the Data Protection Act (1998) requirements 
for fair processing of data). Participants in the nested 
qualitative study who wish to withdraw will be allowed to 
do so. Their data will be retained and used, unless they 
additionally indicate that they wish to withdraw their data.
rAndoMIsAtIon
Randomisation procedures
This is a cluster-randomised, stepped-wedge design trial 
wherein maternity units rather than individual patients 
are randomised. All units will implement the fetal move-
ment monitoring intervention at some point during the 
trial; the random element is the time point at which 
this will occur, the so-called ‘step’ of the stepped-wedge 
design. Participating maternity units will be blinded to 
their randomly allocated time point until the time this is 
required to be revealed to enable the necessary training 
in the implementation of the intervention to be deliv-
ered. Primary and secondary outcomes of the trial will be 
gathered in a blinded manner via routinely collected data 
sources.
Maternity units which are in close proximity to each 
other will be grouped for the purposes of randomisation. 
This will assist with the feasibility of delivering the training 
for and implementation of the intervention. Further-
more, this local synchronisation of the intervention 
implementation will minimise the chances of contamina-
tion (introduction of the intervention prematurely) from 
maternity units which have already implemented the 
intervention to those not yet randomised.
The order in which the groups of maternity units step 
in to implement the intervention will be determined by 
computer-generated random numbers from a uniform 
distribution. The randomisation list will be held by the 
Edinburgh Clinical Trials Unit. The identities of the 
research team staff whose roles in the trial require them 
to be unblinded to randomisation codes will be recorded 
in the trial master file (TMF).
treatment allocation
Participating sites will be randomised to different sched-
ules for implementing the intervention. All units will be 
providing conventional treatment at baseline according to 
local practice—this is the treatment established before the 
study starts. Sites will be randomised to ‘active’ treatment in 
turn as described above. Active treatment will consist of a 
package of care consisting of a management plan for iden-
tification and delivery of the ‘at risk’ fetus, together with 
strategies for increasing pregnant women’s awareness of the 
need to report RFM early. The recommended management 
plan for identification and delivery of the ‘at risk’ fetus is 
shown in figure 2. Practice change in the active units will 
be achieved by: (1) written/email information to all clini-
cians (doctors, midwives and ultrasonographers) in each 
unit about the study protocol and amendment of the local 
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protocol for RFMs to that of the study protocol; (2) a short 
web-based training package taking approximately 1 hour to 
complete for all clinicians in each centre and (3) training/
information sessions to run in each unit and (4) posters 
in each unit to describe the practice change. Strategies 
for encouraging clinicians to increase pregnant women’s 
awareness of fetal movement will include all the above and 
also a fetal movement leaflet for pregnant women (shown 
in online supplementary file 1). The Norwegian quality 
improvement study showed inconclusive results regarding 
the effect of the intervention in non-European women.41 
To attempt to address this, the AFFIRM information leaflet 
was available in 12 languages including: Arabic, Bengali, 
English, Hindi, Hungarian, Latvian, Lithuanian, Mandarin, 
Polish, Russian and Urdu. Furthermore, by including staff 
education which highlighted the need to ask women about 
fetal movements in routine antenatal consultations as many 
women as possible should have received information about 
what to do if they perceive RFM.
Once units have begun active treatment it is not antici-
pated that they will return to conventional treatment. We 
will conduct an audit of women presenting with RFMs 
and assess the proportion of staff completing the online 
training to assess the extent to which sites have followed 
the intervention plan. Units will be informed about treat-
ment allocation as near as possible to the implementation 
of the ‘active’ treatment. For practical purposes, we antic-
ipate that each unit will need around 3 months’ notice 
before the ‘active’ treatment is introduced, hence units 
will be informed of the timing of their treatment alloca-
tion (step) 3 months before the active treatment is due to 
start. The treatment allocation will not be administered 
blind and there are no restrictions on concomitant care 
or other interventions during the study, hence there is no 
need for emergency unblinding and there are no stop-
ping rules for the study.
Figure 2 Flow chart for the management of women presenting with RFMs for sites implementing the AFFIRM study. AC, 
abdominal circumference; CTG, cardiotocography; DVP, deepest vertical pool; EFW, estimated fetal weight; FGR, fetal 
growth restriction; FM, fetal movement; IOL, induction of labour; LV, liquor volume; RCOG, Royal College of Obstetricians and 
Gynaecologists; RFM, reduced fetal movement; USS, ultrasound scan. 
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dAtA CollECtIon
For the main trial, data will be accessed from the informa-
tion routinely collected during the clinical management 
of the patient. For consistency, we will normally only 
include data items which become available within 
4 months after the delivery date in question, although 
we may seek advice from the independently chaired trial 
steering committee (TSC) about exceptions as they arise. 
Different data sources will be used for different regions 
of the study: (1) In Scotland the source data will be SMR2 
and the Scottish Birth record, (2) In Ireland the source 
data will be the National Perinatal Reporting System 
(NPRS http://www. hpo. ie), (3) In Northern Ireland, 
the source data will be the Northern Ireland Maternity 
Statistics database (NIMATS), (4) In England and Wales, 
the source data will be the Office of National Statistics, 
or other relevant body. Data will be collected retrospec-
tively on an annual basis from all sources. We will assume 
that data unavailable 4 months after the woman delivered 
are likely to be unobtainable (but see note in the Study 
design section). Thus, data on the first year of the study 
will be collected at month 16; data on the second year will 
be collected at month 28; and so on.
Data are routinely collected. A formal request for data 
access will be made at the start of the study. This will 
require (1) in Scotland—Privacy Advisory Committee 
approval and a formal approach to NHS Scotland 
Information Services Division, (2) in Ireland a formal 
approach to NPRS, (3) NIMATS in Northern Ireland, (4) 
in England and Wales a formal approach will be made to 
the relevant bodies.
Data will then be sent to the electronic Data Research 
and Innovation Service National Safe Haven (NHS 
National Services Scotland) by secure file transfer 
protocol (or other similar) for storage and subsequent 
analysis within a secure project area (dedicated to the 
AFFIRM study). Further information on the National 
Safe Haven is available at http://www. isdscotland. org/ 
Products- and- Services/ eDRIS/ Becoming- an- eDRIS- 
User/# NSS- National- Safe- Haven. Briefly, the National 
Safe Haven is located on a secure server, in which trusted 
and authorised researchers can analyse individual level 
data while maintaining the utmost confidentiality. It is 
anticipated that all study analyses will be done within the 
Safe Haven, using one of the available statistical packages 
(eg, R, SPSS Version 23).
Identifiers on Scottish data within the National Safe 
Haven are concealed from researchers. Data from 
outwith Scotland will be anonymised before submis-
sion to the National Safe Haven. We propose that data 
submitted to the National Safe Haven will be ‘anony-
mised’ by the data provider. However, we propose that 
the anonymisation link will be retained at the source 
so that it will be possible to relink data retrospectively. 
The rationale for retaining the ability of local data 
guardians to relink data is because it is important to 
retain the possibility of identifying individual patients 
retrospectively. Examples include: (1) It is possible that 
some additional important data may be available at a 
late stage on individual participants—for example, in 
the scenario where the woman or baby had a major 
adverse event and spent a long time in hospital before 
discharge or death and (2) Although our protocol and 
outcome analysis does not require identifiable data, we 
believe this will be a ‘once in a lifetime’ study, and that 
subsequent secondary analyses could yield important 
information for patients and for policymakers. If retro-
spective identification is not possible, this will limit 
further analysis. One likely example of future anal-
yses is to determine the effect of the intervention on 
different causes of stillbirth. This is outwith the scope 
of the current protocol, but could be done relatively 
straightforwardly, by linking nationally recorded infor-
mation on ‘cause’ of stillbirth to our study database. We 
anticipate that such additional analyses would require 
additional ethics approval, but without a process by 
which to relink data, it will not be possible to perform 
such subsequent analyses.
All investigators and study site staff involved with this 
study will comply with the requirements of the Data 
Protection Act 1998 (or equivalent for those outwith the 
UK) with regard to the collection, storage, processing and 
disclosure of personal information and will uphold the 
Act’s core principles. Published results will not contain 
any personal data that could allow identification of an 
individual participant.
In addition to the data recorded above, all sites will be 
asked to provide a copy of their guidelines around (1) 
maternal awareness of RFM and (2) management of 
women presenting with RFM. Copies of guidelines will be 
sought by the study office (A) at the start of the study, 
(B) immediately before initiation of the intervention in 
each specific unit and (C) 6 months after initiation of the 
intervention in each specific unit.
For the nested qualitative study, we will perform inter-
views of healthcare workers and a small nested cohort of 
pregnant women about their experiences of fetal move-
ment and of this intervention. We shall ensure a diversity 
of age and include nulliparous and multiparous women 
(n=30 in total). Ten interviews will be conducted with 
each of the following groups of healthcare providers: 
obstetricians, midwives and sonographers/radiologists. 
The interviews will take a semistructured format (sensi-
tising and piloting interviews will be conducted prior to 
the commencement of the trial and in the first month 
of the nested qualitative study). This format will ensure 
the same categories of data will be obtained from each 
participant but also allow individual responses to be fully 
explored.
stAtIstICs And dAtA AnAlysIs
Sample size calculation
The sample size is the number of women delivering in 
hospitals participating in the study. This was initially 
planned to include sites in Scotland, totalling around 
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58 000 deliveries per year with 16 consultant-led mater-
nity units, 20 smaller units each delivering less than 350 
babies per year, and seven units delivering less than 
five births per year. The units involved in Perinatal 
Ireland (an all-Ireland research consortium across seven 
academic sites in Ireland currently funded by the Health 
Research Board, Ireland) have 50 000 births per year with 
seven large sites. Combining one or two of the smaller 
units and one larger unit into a single ‘hospital group’ 
for each local area could provide 24 hospital ‘groups’—
the details of hospital groupings will be reviewed and 
finalised immediately prior to randomisation. In total, 
36 sites expressed interest in participating in the study, 
although two were unable to participate in the study and 
withdrew before randomisation. In total, 34 units were 
randomised, these were situated throughout the UK and 
Ireland (10 in England, 4 in Ireland, 15 in Scotland and 
5 in Wales) with 143 140 births per annum.
We calculated statistical power using the method-
ology for stepped-wedge designs proposed in Hussey 
and Hughes (2007).42 First, we analysed stillbirth event 
data from the Scottish Perinatal and Infant Mortality and 
Morbidity Report covering years 2005–201017 to deter-
mine estimates of between-unit and within-unit variability 
in stillbirth rate. Analysis was by generalised linear mixed 
model for binary outcomes. The power calculation, as 
per equations (#7) and (#8) in reference 42 assumed: 
significance level 5%; analysis by generalised linear mixed 
model; deliveries equally distributed across hospital 
groupings; baseline stillbirth rate 0.438%17; cluster coeffi-
cient of variation 0.333.
Finally, the statistical power depends on the number 
of groups in which the intervention is implemented at 
each stage of the stepped-wedge design and the dura-
tion of recruitment at each ‘step.’ Our study design 
proposes sequential introduction of the intervention 
into three hospital groups at a time in eight steps at 
4-month intervals. This would give 92.4% power to 
detect a 30% risk reduction under the intervention and 
80.7% power to detect a 25% reduction. A 30% risk 
reduction was seen in the Norwegian study; the antic-
ipated effect sizes of 25% and 30% relative reduction 
take into account that the intervention will not have the 
power to reduce all stillbirths, since 20% of stillbirths 
in Ireland43 and 15% in Scotland17 are associated with 
congenital anomaly.
The power actually achieved in the study will be slightly 
lower, as deliveries during the 2-month ‘transition’ 
period following implementation of the intervention in 
a site will not be included in the analysis. The effect 
of this was explored using the Stata function stepped-
wedge,44 which showed the statistical power would 
become 88.2% (30% risk reduction) and 74.6% (25% 
risk reduction). It is anticipated that unavailability of 
data and women asking to withdraw their data will be 
less than 1%.
Proposed analyses
For the binary primary and secondary outcomes, data 
will be analysed by generalised linear mixed model with 
a random effect for hospital and fixed effects for the 
intervention implementation and study time period. 
A site by intervention interaction random effect will 
be included in the model and retained if it explains an 
important proportion of the variability in outcomes. The 
primary analysis of data will be on an intention to treat 
basis (the design of the trial means it is not possible to 
determine individual patient/caregiver compliance with 
the intervention). An ‘on treatment’ variable will be 
calculated for which women will be grouped as active or 
control according to when the intervention was actually 
implemented in their site, instead of when the site was 
randomised to implement the intervention. The primary 
outcome will be reanalysed in two sensitivity analyses. 
First, we will perform the analysis according to the actual 
timing of the implementation of the intervention rather 
than the randomised timing of the intervention using 
the ‘on treatment’ classification. Second, we will perform 
the analysis in the subgroup of sites who were deemed to 
have implemented the intervention effectively according 
to the perception of the Principal Investigator at each 
site. The accuracy of this perception will be confirmed 
with the findings of a site audit (details in online supple-
mentary file 2). There will be no attempt to correlate the 
impact of the intervention according to the results of the 
site audit.
There are no planned imputations for missing data. 
However, if the missing data rate for smoking status during 
pregnancy is relatively high an imputation technique will 
be devised. The imputation method will be informed 
using smoking history at booking and age at delivery.45 
A prespecified subgroup analysis will be performed for 
babies with and without congenital anomalies, and will be 
implemented by testing for an intervention by congen-
ital anomaly interaction added to the generalised linear 
mixed model described above. No formal interim analyses 
for efficacy or safety will be performed. A full statistical 
analysis plan will be finalised prior to locking of the study 
database.
Qualitative data
For the nested qualitative study, the data will be 
audio-recorded and transcribed. The data will be coded 
thematically and an analytical framework developed to 
make sense of patient experience of fetal movement and 
the intervention and also healthcare providers’ perspec-
tives and experiences. NVivo will be used to support the 
analysis.
Process outcomes
The process outcomes being assessed by the rates of 
induction of labour, number of women presenting with 
RFMs, interval between perceiving fetal movements and 
presenting to hospital will be analysed using the same 
methods as for the main trial, with the exception of the 
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continuous outcome (interval between perceiving fetal 
movements and presenting to hospital) which will be 
analysed using a normal linear mixed model.
AdVErsE EVEnts
This is not a Clinical Trial of an Investigational Medic-
inal Product (CTIMP) so adverse events will not be 
formally reported. Stillbirth and other measures of fetal 
and maternal morbidity are outcomes of the study. The 
purpose of the intervention is to reduce such adverse 
events. Therefore, due to the low risks for this trial, a sepa-
rate Data Monitoring Committee (DMC) is not required 
and the TSC will cover any responsibilities normally allo-
cated to a DMC. If considered necessary, the TSC may 
review unblinded data for the study, including morbidity 
and mortality indices. No other adverse event reporting 
will be undertaken.
trIAl MAnAgEMEnt And oVErsIght ArrAngEMEnts
The trial will be coordinated by a Project Management 
Group, consisting of the grant holders and the Trial 
Manager. The Chief Investigator (JEN) will lead the 
project management group. The Trial Manager will 
oversee the study and will be accountable to the Chief 
Investigator. A TSC will be established to oversee the 
conduct and progress of the trial. The terms of refer-
ence and a draft template for reporting will be ratified 
in one of the early meetings of the TSC.
Investigators and institutions involved in the study will 
permit trial-related monitoring and audits on behalf of 
the cosponsors (Academic and Clinical Central Office 
for Research & Development—joint office for Univer-
sity of Edinburgh and NHS Lothian, Sponsor contact: 
ray. french@ ed. ac. uk), research ethics committee (REC) 
review and regulatory inspection(s). In the event of an 
audit or monitoring, the Investigator agrees to allow the 
representatives of the sponsor direct access to all study 
records and source documentation. In the event of 
regulatory inspection, the Investigator agrees to allow 
inspectors direct access to all study records and source 
documentation.
study monitoring and audit
The sponsor determined that as no individual partici-
pants were recruited to the intervention, and it was not 
a CTIMP no formal monitoring and audit was required.
good clinical practice and ethical conduct
The study will be conducted in accordance with the 
principles of the research governance framework opera-
tional and good clinical practice in the relevant country. 
A favourable ethical opinion has been obtained from 
the Scotland A REC (Reference 13/SS/0001) and local 
research and development approval has been obtained 
prior to commencement of the study.
Local study investigator(s) will be appointed to each 
site (or for small units, groups of sites). She/He will be 
responsible for the overall conduct of the study at the 
site and compliance with the protocol and any protocol 
amendments.
study ConduCt rEsPonsIbIlItIEs
Protocol amendments
Any changes in research activity, except those necessary 
to remove an apparent, immediate hazard to the partic-
ipant in the case of an urgent safety measure, will be 
reviewed and approved by the Chief Investigator and 
Sponsor. Amendments to the protocol will be submitted 
in writing to the appropriate REC and local Research 
and Development (R&D) department for approval 
prior to participants being enrolled into an amended 
protocol.
Protocol violations and deviations
Investigators will not implement any deviation from the 
protocol without agreement from the Chief Investigator 
and appropriate REC and R&D department approval 
except where necessary to eliminate an immediate hazard 
to trial participants. In the event that an Investigator needs 
to deviate from the protocol, the nature of and reasons 
for the deviation will be recorded. If this necessitates a 
subsequent protocol amendment, this will be submitted 
to the REC, and local R&D department for review and 
approval if appropriate.
serious breach requirements
A serious breach is one which is likely to effect to a signif-
icant degree (A) the safety or physical or mental integrity 
of the participants of the trial; or (B) the scientific value 
of the trial. If a potential serious breach is identified by 
the Chief investigator, Principal Investigator or delegates, 
the cosponsors ( accord. seriousbreach@ ed. ac. uk) will 
be notified within 24 hours. It will be the responsibility 
of the cosponsors to assess the impact of the breach on 
the scientific value of the trial, to determine whether the 
incident constitutes a serious breach and, if so, report it 
to the REC.
All violations will be assessed by the sponsor(s) to ascer-
tain if they meet the criteria for a serious breach. If the 
sponsor(s) deem the incident to be a violation that does not 
constitute a serious breach from the protocol when identi-
fied, corrective and preventative actions will be taken where 
appropriate and they will be recorded in file notes, held 
within the TMF and Investigator Site File.
study record retention
All study documentation will be kept for a minimum of 5 
years from the protocol defined end of study point. When 
the minimum retention period has elapsed, study docu-
mentation will not be destroyed without permission from 
the sponsor.
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End of study
The end of study date was finalised in the protocol 
after the study commenced; the agreed end of study 
date is 31 December 2016. The Investigators and/or 
the TSC and/or the cosponsor(s) have the right at any 
time to terminate the study for clinical or administra-
tive reasons.
The end of the study will be reported to the REC within 
90 days, or 15 days if the study is terminated prema-
turely. The Investigators will inform participants of the 
premature study closure and ensure that the appropriate 
follow-up is arranged for all participants involved. A 
summary report of the study will be provided to the REC 
and Regulatory Authority within 1 year of the end of the 
study.
rEPortIng, PublICAtIons And notIFICAtIon oF rEsults
Ownership of the data arising from this study resides with 
the study team. On completion of the study, the study data 
will be analysed and tabulated, and a clinical study report will 
be prepared in accordance with good clinical practice guide-
lines. The clinical study report will be used as the basis for 
publication and presentation at scientific meetings. Investi-
gators have the right to publish orally or in writing the results 
of the study. Summaries of results will also be made available 
to Investigators for dissemination within their clinics (where 
appropriate and according to their discretion).
dIsCussIon
The data provided by this study will inform the informa-
tion given to women about RFMs and their management 
when they present to maternity services; which has been 
recurrently identified by Confidential Enquiries into 
antepartum stillbirths as suboptimal.27 28 Data from the 
AFFIRM study will be able to be compared with results 
from two other active studies which aim to improve 
mothers’ awareness and reporting of RFMs. My Babies 
Movement (ACTRN 12614000291684) is a stepped-wedge 
cluster trial of a mobile phone application to help women 
get to know their babies’ movements, to be mindful of 
movements every day and not to wait to report concerns 
to their maternity care provider. The Mindfetalness 
study (NCT02865759) is a cluster trial of 39 000 women 
randomised to routine antenatal care or the Mindfetal-
ness brochure and website.46 Women participating in the 
Mindfetalness process will spend 15 min each day getting 
to know their babies’ movements and will specifically 
be encouraged to contact their health provider if they 
perceive RFMs. This primary outcome of this study is an 
Apgar score <7 at 5 min; stillbirth and perinatal deaths will 
be recorded as tertiary endpoints of this study.46 These 
large studies will provide much needed robust evidence 
to determine whether increased maternal awareness 
of RFMs combined with a standardised management 
protocol to identify acute or chronic fetal compromise 
can reduce stillbirth.33
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